744 related articles for article (PubMed ID: 23369096)
21. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of P-gp transporter by goniothalamin derivatives sensitizes resistant cancer cells to chemotherapy.
Sachs J; Kadioglu O; Weber A; Mundorf V; Betz J; Efferth T; Pietruszka J; Teusch N
J Nat Med; 2019 Jan; 73(1):226-235. PubMed ID: 30066239
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
25. Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells.
Chang YT; Wang CCN; Wang JY; Lee TE; Cheng YY; Morris-Natschke SL; Lee KH; Hung CC
Phytomedicine; 2019 Feb; 53():252-262. PubMed ID: 30668405
[TBL] [Abstract][Full Text] [Related]
26. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
27. The role of ABC transporters in clinical practice.
Leonard GD; Fojo T; Bates SE
Oncologist; 2003; 8(5):411-24. PubMed ID: 14530494
[TBL] [Abstract][Full Text] [Related]
28. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
29. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
Zhang Q; Li F
Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
[TBL] [Abstract][Full Text] [Related]
30. Nanocarrier-based co-delivery approaches of chemotherapeutics with natural P-glycoprotein inhibitors in the improvement of multidrug resistance cancer therapy.
Md S; Alhakamy NA; Sharma P; Ansari MS; Gorain B
J Drug Target; 2022 Sep; 30(8):801-818. PubMed ID: 35465812
[TBL] [Abstract][Full Text] [Related]
31. Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors.
Syed SB; Lin SY; Arya H; Fu IH; Yeh TK; Charles MRC; Periyasamy L; Hsieh HP; Coumar MS
Chem Biol Drug Des; 2021 Jan; 97(1):51-66. PubMed ID: 32633857
[TBL] [Abstract][Full Text] [Related]
32. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
33. SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.
Xu SW; Law BYK; Qu SLQ; Hamdoun S; Chen J; Zhang W; Guo JR; Wu AG; Mok SWF; Zhang DW; Xia C; Sugimoto Y; Efferth T; Liu L; Wong VKW
Pharmacol Res; 2020 Mar; 153():104660. PubMed ID: 31982489
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein inhibition: the past, the present and the future.
Darby RA; Callaghan R; McMahon RM
Curr Drug Metab; 2011 Oct; 12(8):722-31. PubMed ID: 21434857
[TBL] [Abstract][Full Text] [Related]
35. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
36. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives.
Fusi F; Saponara S; Valoti M; Dragoni S; D'Elia P; Sgaragli T; Alderighi D; Kawase M; Shah A; Motohashi N; Sgaragli G
Curr Drug Targets; 2006 Aug; 7(8):949-59. PubMed ID: 16918323
[TBL] [Abstract][Full Text] [Related]
37. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
Patel NR; Rathi A; Mongayt D; Torchilin VP
Int J Pharm; 2011 Sep; 416(1):296-9. PubMed ID: 21703341
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
39. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells.
Dinić J; Podolski-Renić A; Jovanović M; Musso L; Tsakovska I; Pajeva I; Dallavalle S; Pešić M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527404
[TBL] [Abstract][Full Text] [Related]
40. Potential of Natural-Based Anticancer Compounds for P-Glycoprotein Inhibition.
Dinić J; Podolski-Renić A; Jeremić M; Pešić M
Curr Pharm Des; 2018; 24(36):4334-4354. PubMed ID: 30648503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
